Gene Therapy Journal Citation Rate 2026
0969-7128
eISSN 1476-5462
Springer Nature
GB
Q1 Quartile Established Impact
About Gene Therapy
Gene Therapy (GT) is a peer-reviewed academic journal covering CAR-T cell therapy research and CRISPR and Genetic Engineering, published by Springer Nature in GB, catalogued under ISSN 0969-7128 (e-ISSN 1476-5462). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 3.40 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$4990 USD).
Gene Therapy Citation Rate 2026 — In Context
Gene Therapy has a 2025 2-Year Citation Rate (OpenAlex) of 3.40, placing it in the Q1 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Gene Therapy operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Gene Therapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Gene Therapy against similar journals in the field, use our journal comparison tool.
Submission Tips for Gene Therapy
- Budget $4990 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers CAR-T cell therapy research, CRISPR and Genetic Engineering, RNA Interference and Gene Delivery. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Gene Therapy Compares
Compared against 28 journals in the same research areas.
| ISSN (Print) | 0969-7128 |
|---|---|
| ISSN (Online) | 1476-5462 |
| Publisher | Springer Nature |
| Country | United Kingdom |
| APC / Cost | $4990 USD |
In-depth profile & metrics
Gene Therapy is published by Springer Nature and based in United Kingdom. It runs on a subscription or hybrid model with an article-processing charge of USD 4990.
In our subject taxonomy, Gene Therapy is classified under CAR-T cell therapy research, CRISPR and Genetic Engineering, RNA Interference and Gene Delivery and Viral Infectious Diseases and Gene Expression in Insects.
Gene Therapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 3.403.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Gene Therapy
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 3.403 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Gene Therapy against similar publications in its field:
Related Journals in Your Field
-
Advanced Drug Delivery Reviews Elsevier BV IF 12.22
-
Journal of Nanobiotechnology BioMed Central IF 11.11
-
Theranostics Ivyspring International Publisher IF 10.23
-
Journal for ImmunoTherapy of Cancer BMJ IF 7.57
-
Drug Discovery Today Elsevier BV IF 7.11
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S65405509
Get weekly updates for CAR-T cell therapy research journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.